Low-expression of microRNA-107 inhibits cell apoptosis in glioma by upregulation of SALL4

He, Jié; Zhang, Wanyu; Zhou, Qinglong; Zhao, Tianshu; Song, Yuwen; Chai, Li; Yu, Li

doi:10.1016/j.biocel.2013.06.008

Cited by 65 publications

(53 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These findings support that the tumor suppressive role of miR-219 in glioma cells is, at least partly, via inhibition of SALL4 expression. Similarly, a previous study reported that miR-107 inhibited glioma cell proliferation and induced cell apoptosis via directly targeting SALL4 (27). Therefore, the present study further highlights the importance of the miR/SALL4 axis in glioma.…”

Section: Discussionsupporting

confidence: 50%

MicroRNA‑219 exerts a tumor suppressive role in glioma via targeting Sal‑like protein 4

Jiang

et al. 2017

Exp Ther Med

View full text Add to dashboard Cite

Abstract. MicroRNAs (miRs) serve important roles in the development and progression of various human cancer types, including glioma. Recently, miR-219 has been suggested to function as a tumor suppressor in glioma; however, the underlying mechanism remains largely unknown. The aim of this study was to investigate the regulatory mechanism of miR-219 in the malignant phenotypes of glioma cells. Quantitative polymerase chain reaction (qPCR) and western blotting were conducted to examine the mRNA and protein expression. An MTT assay, wound healing assay and Transwell assay were used to study cell proliferation, migration and invasion. The qPCR data indicated that the expression of miR-219 was significantly decreased in glioma tissues compared with normal brain tissues. In addition, a low expression of miR-219 was identified to be associated with an advanced pathological grade. In vitro experiments demonstrated that miR-219 was also downregulated in several common glioma cell lines, including A172, U87, U251 and U373, when compared with that in normal astrocytes. Ectopic expression of miR-219 caused a significant decrease in U87 cell proliferation, migration and invasion. Luciferase reporter assay data indicated that Sal-like protein 4 (SALL4) was a direct target gene of miR-219, while the protein expression of SALL4 was negatively regulated by miR-219 in U87 cells. Furthermore, SALL4 was significantly upregulated in glioma tissues and cell lines, and upregulation of SALL4 was associated with a higher pathological grade. Furthermore, overexpression of SALL4 significantly attenuated the suppressive effects of miR-219 on U87 cell proliferation, migration and invasion, suggesting that miR-219 serves a suppressive role in glioma growth and metastasis via targeting SALL4. Therefore, the present study highlighted the clinical significance of the miR-219/SALL4 axis in glioma.

show abstract

Section: Discussionsupporting

confidence: 50%

MicroRNA‑219 exerts a tumor suppressive role in glioma via targeting Sal‑like protein 4

Jiang

et al. 2017

Exp Ther Med

View full text Add to dashboard Cite

show abstract

“…CDX1-induced SALL4 converts gastric epithelial cells into tissue stem-like progenitor cells, which then transdifferentiate into intestinal epithelial cells, suggesting that SALL4 is a critical component of CDX1-directed transcriptional circuitry that promotes intestinal metaplasia. Furthermore, SALL4 is found to be regulated by microRNA in glioma cells [48]. MiR-107 mimics reduce while miR-107 inhibitors increase the SALL4 mRNA level.…”

Section: Sall4 Regulation In Cancermentioning

confidence: 99%

SALL4: An emerging cancer biomarker and target

et al. 2015

View full text Add to dashboard Cite

“…Regarding the function of miR-107 in cancer, reduced miR-107 expression has been reported in various types of cancer [69][70][71][72][73][74][75][76][77][78] , and several recent studies have identified the tumor suppressor functions of miR-107. One crucial function of miR-107 that has been identified is the inhibition of oncogenes, such as CDK8 in breast cancer 71 , the ATR/Chk1 pathway in cervical cancer 79 , HIF-1, CCND1, and NFKB1 in colon cancer 80,81 , CDK in gastric cancer 70 , CDK6, Notch-2, and VEGF in glioma Expression profiles of miR-107 in human organs.…”

Section: Discussionmentioning

confidence: 99%

Depleted Tumor Suppressor miR-107 in Plasma Relates to Tumor Progression and Is a Novel Therapeutic Target in Pancreatic Cancer

Imamura

Komatsu

Ichikawa

et al. 2017

Journal of the American College of Surgeons

View full text Add to dashboard Cite

This study explored decreased tumor suppressor microRNA (miRNA) plasma levels in pancreatic cancer (PCa) patients to clarify their potential as novel biomarkers and therapeutic targets. We used the microRNA array-based approach to select candidates by comparing plasma levels between PCa patients and healthy volunteers. Six down-regulated miRNAs (miR-107, miR-126, miR-451, miR-145, miR-491-5p, and miR-146b-5p) were selected. Small-and large-scale analyses using samples from 100 PCa patients and 80 healthy volunteers revealed that miR-107 was the most down-regulated miRNA in PCa patients compared with healthy volunteers (P < 0.0001; area under the receiver-operating characteristic curve, 0.851). A low miR-107 plasma level was significantly associated with advanced T stage, N stage, and liver metastasis and was an independent factor predicting poor prognosis in PCa patients (P = 0.0424; hazard ratio, 2.95). miR-107 overexpression in PCa cells induced G1/S arrest with the production of p21 and inhibited cell proliferation through the transcriptional regulation of Notch2. In vivo, the restoration and maintenance of the miR-107 plasma level significantly inhibited tumor progression in mice. Depletion of the tumor suppressor miR-107 in plasma relates to tumor progression and poor outcomes. The restoration of the plasma miR-107 level might be a novel anticancer treatment strategy for PCa.Pancreatic cancer (PCa) is the fourth leading cause of cancer-related death in Japan and the United States 1 and the seventh worldwide 2 . PCa is one of the most aggressive cancer types and constitutes a global health problem, with more than 330,000 cancer-related deaths annually 2 . Although perioperative chemo-and/or radiotherapy regimens, surgical techniques and perioperative management have greatly progressed, PCa continues to present an extremely poor prognosis. Even now, the median survival time of PCa patients is 5 to 8 months, and their 5-year survival rate is less than 10%. This is because PCa develops with no symptoms, local invasiveness, or metastases to distant organs in the early stage of its clinical course [3][4][5] . Therefore, novel early diagnostic tools and effective treatment strategies are urgently needed to improve the survival rate of PCa patients.Because understanding the molecular mechanisms of tumorigenesis and identifying clinical biomarkers and molecular targets for PCa contribute to improving the management of this lethal disease, several studies have attempted to detect the biological factors involved in the malignant potential of PCa 6, 7 . Nevertheless, in clinical settings, no molecule has been used as an early diagnostic biomarker, and only a few molecules have been

show abstract

Low-expression of microRNA-107 inhibits cell apoptosis in glioma by upregulation of SALL4

Cited by 65 publications

References 32 publications

MicroRNA‑219 exerts a tumor suppressive role in glioma via targeting Sal‑like protein 4

MicroRNA‑219 exerts a tumor suppressive role in glioma via targeting Sal‑like protein 4

SALL4: An emerging cancer biomarker and target

Depleted Tumor Suppressor miR-107 in Plasma Relates to Tumor Progression and Is a Novel Therapeutic Target in Pancreatic Cancer

Contact Info

Product

Resources

About